Surgery Partners, Inc. Announces Second Quarter 2024 Results Raises Full Year 2024 Guidance
Surgery Partners, Inc. (NASDAQ:SGRY) reported strong Q2 2024 results, raising full-year guidance. Key highlights include:
- Revenues increased 14.2% to $762.1 million
- Same-facility revenues up 9.9%
- Adjusted EBITDA grew 18.1% to $118.3 million
- Adjusted EBITDA margin expanded 50 basis points to 15.5%
- Full-year guidance raised to >$3.075 billion revenue and >$508 million Adjusted EBITDA
The company deployed nearly $220 million on acquisitions and improved its balance sheet position. Cash and cash equivalents stood at $213.5 million, with $647.8 million available under its revolving credit facility. The total net debt to EBITDA ratio was approximately 3.8x at quarter-end.
Surgery Partners, Inc. (NASDAQ:SGRY) ha riportato risultati solidi nel secondo trimestre del 2024, aumentando le previsioni per l'intero anno. Le principali evidenze includono:
- I ricavi sono aumentati del 14,2% a $762,1 milioni
- I ricavi della stessa struttura sono aumentati del 9,9%
- L'EBITDA rettificato è cresciuto del 18,1% a $118,3 milioni
- Il margine di EBITDA rettificato è aumentato di 50 punti base al 15,5%
- Le previsioni per l'intero anno sono state riviste a oltre $3,075 miliardi di ricavi e oltre $508 milioni di EBITDA rettificato
La società ha investito quasi $220 milioni in acquisizioni migliorando la propria posizione patrimoniale. La liquidità e gli equivalenti di liquidità ammontavano a $213,5 milioni, con $647,8 milioni disponibili sotto la propria linea di credito revolving. Il rapporto totale debito netto su EBITDA era di circa 3,8x alla fine del trimestre.
Surgery Partners, Inc. (NASDAQ:SGRY) reportó resultados sólidos en el segundo trimestre de 2024, elevando las proyecciones para todo el año. Los puntos clave incluyen:
- Los ingresos aumentaron un 14.2% a $762.1 millones
- Los ingresos por instalaciones similares crecieron un 9.9%
- El EBITDA ajustado creció un 18.1% a $118.3 millones
- El margen de EBITDA ajustado se amplió en 50 puntos base al 15.5%
- Las proyecciones para el año completo se elevan a más de $3.075 mil millones en ingresos y más de $508 millones en EBITDA ajustado
La compañía destinará casi $220 millones a adquisiciones y mejoró su posición en el balance. El efectivo y equivalentes de efectivo totalizaron $213.5 millones, con $647.8 millones disponibles bajo su línea de crédito revolving. La ratio total de deuda neta a EBITDA fue de aproximadamente 3.8x al final del trimestre.
Surgery Partners, Inc. (NASDAQ:SGRY)가 2024년 2분기에 강력한 실적을 보고하며 연간 가이던스를 상향했습니다. 주요 하이라이트는 다음과 같습니다:
- 매출 14.2% 증가하여 $762.1백만 달러
- 동일 시설 매출 9.9% 증가
- 조정된 EBITDA 18.1% 성장하여 $118.3백만 달러
- 조정된 EBITDA 마진 50bp 증가하여 15.5%에 도달
- 연간 가이던스를 30억 7500만 달러 이상의 매출 및 5억 800만 달러 이상의 조정 EBITDA로 상향
회사는 거의 $220백만 달러를 인수에 투자하며 재무 상태를 개선했습니다. 현금 및 현금성 자산은 $213.5백만 달러였으며, 회전 신용 한도 내에서 $647.8백만 달러를 이용할 수 있었습니다. 분기 말 기준으로 총 순 부채 대 EBITDA 비율은 약 3.8배였습니다.
Surgery Partners, Inc. (NASDAQ:SGRY) a annoncé de solides résultats au deuxième trimestre 2024, révisant à la hausse ses prévisions pour l'année entière. Les points saillants incluent:
- Les revenus ont augmenté de 14,2 % pour atteindre 762,1 millions de dollars
- Les revenus des mêmes établissements ont augmenté de 9,9 %
- L'EBITDA ajusté a crû de 18,1 % pour atteindre 118,3 millions de dollars
- La marge d'EBITDA ajusté a augmenté de 50 points de base pour atteindre 15,5 %
- Les prévisions pour l'année complète ont été relevées à plus de 3,075 milliards de dollars de revenus et à plus de 508 millions de dollars d'EBITDA ajusté
La société a déployé près de 220 millions de dollars dans des acquisitions et a amélioré sa situation financière. La trésorerie et les équivalents de trésorerie s'élevaient à 213,5 millions de dollars, avec 647,8 millions de dollars disponibles dans le cadre de sa ligne de crédit revolving. Le ratio total de dette nette à EBITDA était d'environ 3,8x à la fin du trimestre.
Surgery Partners, Inc. (NASDAQ:SGRY) meldete starke Ergebnisse im 2. Quartal 2024 und erhöhte die Jahresprognose. Wesentliche Highlights umfassen:
- Die Einnahmen stiegen um 14,2% auf 762,1 Millionen USD
- Die Einnahmen aus denselben Einrichtungen stiegen um 9,9%
- Das bereinigte EBITDA wuchs um 18,1% auf 118,3 Millionen USD
- Die bereinigte EBITDA-Marge erweiterte sich um 50 Basispunkte auf 15,5%
- Die Jahresprognose wurde auf über 3,075 Milliarden USD Umsatz und über 508 Millionen USD bereinigtes EBITDA angehoben
Das Unternehmen investierte fast 220 Millionen USD in Akquisitionen und verbesserte seine Bilanzposition. Die liquiden Mittel und Zahlungsmitteläquivalente beliefen sich auf 213,5 Millionen USD, mit 647,8 Millionen USD, die unter seiner revolvierenden Kreditlinie zur Verfügung standen. Das Verhältnis von Nettoverschuldung zu EBITDA betrug zum Ende des Quartals etwa 3,8x.
- Revenue increased 14.2% year-over-year to $762.1 million
- Same-facility revenues grew 9.9% compared to the prior year period
- Adjusted EBITDA increased 18.1% to $118.3 million
- Adjusted EBITDA margin expanded 50 basis points to 15.5%
- Full-year guidance raised for both revenue and Adjusted EBITDA
- Deployed nearly $220 million on strategic acquisitions
- Improved balance sheet position through refinancing actions
- Net loss attributable to Surgery Partners, Inc. was $15.5 million
- Total net debt to EBITDA ratio remains relatively high at 3.8x
Insights
Surgery Partners' Q2 2024 results demonstrate robust growth and operational efficiency. Revenue increased by
The company's strategic focus on acquisitions is evident, with
Surgery Partners' performance underscores the ongoing shift towards outpatient care and ambulatory surgery centers (ASCs). The
The
Surgery Partners' Q2 results and raised guidance reflect broader market trends favoring outpatient surgical facilities. The
The company's aggressive acquisition strategy, evidenced by the
BRENTWOOD, Tenn., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced results for the second quarter ended June 30, 2024.
- Revenues increased
14.2% to$762.1 million compared to the prior year period- Same-facility revenues increased
9.9% - Same-facility cases increased
3.9%
- Same-facility revenues increased
- Net loss attributable to Surgery Partners, Inc. was
$15.5 million - Adjusted EBITDA was
$118.3 million , representing18.1% growth compared to the prior year period
- Adjusted EBITDA was
- Adjusted EBITDA margin was
15.5% , expanding 50 basis points from the prior year period - Full year guidance raised to greater than
$3.07 5 billion in revenue and greater than$508 million in Adjusted EBITDA
Wayne DeVeydt, Executive Chairman of the Board of Surgery Partners, noted, "We are proud to report strong growth in Adjusted EBITDA and revenue, both ahead of our expectations. We achieved these results by continuing to focus on exceptional clinical quality and value, operational execution and the strategic impact of physician recruiting and acquisitions. Our same-facility revenue growth of
Eric Evans, Chief Executive Officer, stated, "In addition to the strength of operational results for the quarter, we continued executing on our acquisition strategy by deploying nearly
Dave Doherty, Chief Financial Officer, commented, "Over the last nine months, the Company has addressed its balance sheet exposure to refinancing and interest rates, having refinanced our term loan and unsecured bonds, increased the borrowing capacity of our revolver and lowered our overall interest rates. In the second quarter, we repriced the term loan to a more favorable rate and fully hedged those rates using interest rate caps. These actions position our balance sheet to fully support the Company’s continued long-term growth."
Second Quarter 2024 Results
Revenues for the second quarter of 2024 increased
Year-to-Date 2024 Results
Revenues year-to-date 2024 increased
Liquidity
Surgery Partners had cash and cash equivalents of
Year-to-date, operating cash flows were
The Company’s ratio of total net debt to EBITDA, as calculated under the Company’s credit agreement, was approximately 3.8x at the end of the second quarter of 2024.
2024 Outlook
The Company raised its outlook for 2024 revenues to be greater than
Conference Call Information
Surgery Partners will hold a conference call today, August 6, 2024 at 8:30 a.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-800-579-2543, or for international callers, 1-785-424-1789. The conference ID for the live call is SPI2Q24. A replay will be available three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the replay is 11156615. The replay will be available until August 20, 2024.
Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company's website at www.surgerypartners.com. The replay will also be available on this same website for a limited time following the call.
To learn more about Surgery Partners, please visit the Company's website at www.surgerypartners.com. Surgery Partners uses its website as a channel of distribution for material Company information. Financial and other material information regarding Surgery Partners is routinely posted on the Company's website and is readily accessible.
About Surgery Partners
Headquartered in Brentwood, Tennessee, Surgery Partners is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high quality, cost effective solutions for surgical and related ancillary care in support of both patients and physicians. Founded in 2004, Surgery Partners is one of the largest and fastest growing surgical services businesses in the country, with more than 200 locations in 33 states, including ambulatory surgery centers, surgical hospitals, multi-specialty physician practices and urgent care facilities. For additional information, visit www.surgerypartners.com.
Forward-Looking Statements
This press release contains forward-looking statements, including those regarding growth, our anticipated operating results for future periods and other similar statements. These statements can be identified by the use of words such as "believes," "anticipates," "expects," "intends," "plans," "continues," "estimates," "predicts," "projects," "forecasts," "may," "could," and similar expressions. All forward-looking statements are based on current expectations and beliefs as of the date of this release and are subject to risks, uncertainties and other factors that may cause actual results to differ materially from the expectations discussed in, or implied by, the forward-looking statements. Many of these factors are beyond our ability to control or predict including, without limitation, reductions in payments from government health care programs and private insurance payors, such as health maintenance organizations, preferred provider organizations, and other managed care organizations and employers; our ability to contract with private insurance payors; changes in our payor mix or surgical case mix; failure to maintain or develop relationships with physicians on beneficial or favorable terms, or at all; the impact of payor controls designed to reduce the number of surgical procedures; our efforts to integrate operations of acquired businesses and surgical facilities, attract new physician partners, or acquire additional surgical facilities; supply chain issues, including shortages or quality control issues with surgery-related products, equipment and medical supplies; competition for physicians, nurses, strategic relationships, acquisitions and managed care contracts; our ability to attract and retain qualified health care professionals; our ability to enforce non-compete restrictions against our physicians; our ability to manage material liabilities whether known or unknown incurred as a result of acquiring surgical facilities; the impact of future legislation and other health care regulatory reform actions, and the effect of that legislation and other regulatory actions on our business; our ability to comply with current health care laws and regulations; the outcome of legal and regulatory proceedings that have been or may be brought against us; the impact of cybersecurity attacks or intrusions, changes in the regulatory, economic and other conditions of the states where our surgical facilities are located; our indebtedness; the social and economic impact of a pandemic, epidemic or outbreak of a contagious disease, such as COVID-19, on our business; and the risks and uncertainties identified and discussed from time to time in the Company’s reports filed with the SEC, including in Item 1A under the heading "Risk Factors" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and other reports filed with the SEC. Except as required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements to reflect events or circumstances after the date of this report, or to reflect the occurrence of unanticipated events or circumstances.
Use of Non-GAAP Financial Measures
In addition to the results prepared in accordance with generally accepted accounting principles in the United States ("GAAP") provided throughout this press release, Surgery Partners has presented the following non-GAAP financial measures: Adjusted net income (loss) attributable to common stockholders, Adjusted net income (loss) per share attributable to common stockholders, Adjusted EBITDA, Adjusted EBITDA related to unconsolidated affiliates, and Free Cash Flow, which exclude various items detailed in the "Reconciliation of Non-GAAP Financial Measures" below.
These non-GAAP financial measures are not intended to replace financial performance measures determined in accordance with GAAP. Rather, they are presented as supplemental measures of the Company's performance that management believes may enhance the evaluation of the Company's ongoing operating results. These non-GAAP financial measures are not presented in accordance with GAAP, and the Company’s computation of these non-GAAP financial measures may vary from similar measures used by other companies. These measures have limitations as an analytical tool and should not be considered in isolation or as a substitute or alternative to revenue, net income or loss, operating income or loss, cash flows from operating activities, total indebtedness or any other measures of operating performance, liquidity or indebtedness derived in accordance with GAAP.
| SURGERY PARTNERS, INC. Selected Consolidated Financial Data (Dollars in millions, except per share amounts, shares in thousands) (Unaudited) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Revenues | $ | 762.1 | $ | 667.6 | $ | 1,479.5 | $ | 1,333.8 | ||||||||
| Operating expenses: | ||||||||||||||||
| Salaries and benefits | 223.2 | 195.2 | 438.4 | 397.4 | ||||||||||||
| Supplies | 199.7 | 182.2 | 388.5 | 370.6 | ||||||||||||
| Professional and medical fees | 92.4 | 72.9 | 175.0 | 147.5 | ||||||||||||
| Lease expense | 22.2 | 21.8 | 43.6 | 43.2 | ||||||||||||
| Other operating expenses | 45.4 | 41.4 | 99.5 | 87.0 | ||||||||||||
| Cost of revenues | 582.9 | 513.5 | 1,145.0 | 1,045.7 | ||||||||||||
| General and administrative expenses | 40.3 | 31.2 | 73.5 | 63.2 | ||||||||||||
| Depreciation and amortization | 34.8 | 24.4 | 68.5 | 58.1 | ||||||||||||
| Transaction and integration costs | 19.3 | 12.0 | 36.7 | 24.5 | ||||||||||||
| Net loss (gain) on disposals, consolidations and deconsolidations | 5.3 | (8.8 | ) | 6.8 | 1.7 | |||||||||||
| Equity in earnings of unconsolidated affiliates | (4.4 | ) | (2.6 | ) | (7.1 | ) | (5.9 | ) | ||||||||
| Litigation settlement | 0.5 | 1.5 | (1.3 | ) | 4.5 | |||||||||||
| Loss on debt extinguishment | 5.1 | — | 5.1 | — | ||||||||||||
| Other income, net | (6.5 | ) | (1.2 | ) | (8.5 | ) | (2.0 | ) | ||||||||
| 677.3 | 570.0 | 1,318.7 | 1,189.8 | |||||||||||||
| Operating income | 84.8 | 97.6 | 160.8 | 144.0 | ||||||||||||
| Interest expense, net | (51.5 | ) | (47.7 | ) | (98.8 | ) | (94.5 | ) | ||||||||
| Income before income taxes | 33.3 | 49.9 | 62.0 | 49.5 | ||||||||||||
| Income (expense) tax benefit | (4.9 | ) | 7.8 | (9.3 | ) | 9.4 | ||||||||||
| Net income | 28.4 | 57.7 | 52.7 | 58.9 | ||||||||||||
| Less: Net income attributable to non-controlling interests | (43.9 | ) | (38.8 | ) | (80.6 | ) | (64.9 | ) | ||||||||
| Net (loss) income attributable to Surgery Partners, Inc. | $ | (15.5 | ) | $ | 18.9 | $ | (27.9 | ) | $ | (6.0 | ) | |||||
| Net (loss) income per share attributable to common stockholders | ||||||||||||||||
| Basic | $ | (0.12 | ) | $ | 0.15 | $ | (0.22 | ) | $ | (0.05 | ) | |||||
| Diluted (1) | $ | (0.12 | ) | $ | 0.15 | $ | (0.22 | ) | $ | (0.05 | ) | |||||
| Weighted average common shares outstanding | ||||||||||||||||
| Basic | 126,134 | 125,718 | 126,053 | 125,463 | ||||||||||||
| Diluted (1) | 126,134 | 127,370 | 126,053 | 125,463 | ||||||||||||
(1) The impact of potentially dilutive securities for the three months ended June 30, 2024 and the six months ended June 30, 2024 and 2023 was not considered because the effect would be anti-dilutive.
| SURGERY PARTNERS, INC. Selected Financial and Operating Data (Dollars in millions, except per case and per share amounts) (Unaudited) | ||||||||
| June 30, 2024 | December 31, 2023 | |||||||
| Balance Sheet Data (at period end): | ||||||||
| Cash and cash equivalents | $ | 213.5 | $ | 195.9 | ||||
| Total current assets | 1,012.5 | 895.0 | ||||||
| Total assets | 7,488.6 | 6,876.7 | ||||||
| Current maturities of long-term debt | 92.4 | 73.3 | ||||||
| Total current liabilities | 551.8 | 523.0 | ||||||
| Long-term debt, less current maturities | 3,039.7 | 2,701.8 | ||||||
| Total liabilities | 3,870.2 | 3,514.8 | ||||||
| Non-controlling interests—redeemable | 442.1 | 327.4 | ||||||
| Total Surgery Partners, Inc. stockholders' equity | 1,952.4 | 1,987.2 | ||||||
| Non-controlling interests—non-redeemable | 1,223.9 | 1,047.3 | ||||||
| Total stockholders' equity | 3,176.3 | 3,034.5 | ||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Cash Flow Data: | ||||||||||||||||
| Net cash provided by (used in): | ||||||||||||||||
| Operating activities | $ | 82.8 | $ | 52.1 | $ | 123.5 | $ | 126.6 | ||||||||
| Investing activities | (244.1 | ) | (71.2 | ) | (327.2 | ) | (141.9 | ) | ||||||||
| Purchases of property and equipment | (26.9 | ) | (25.8 | ) | (47.9 | ) | (50.1 | ) | ||||||||
| Payments for acquisitions, net of cash acquired | (210.0 | ) | (2.8 | ) | (264.6 | ) | (43.5 | ) | ||||||||
| Purchases of equity investments | 0.3 | (38.8 | ) | (1.7 | ) | (48.4 | ) | |||||||||
| Financing activities | 189.6 | (49.0 | ) | 221.3 | (90.2 | ) | ||||||||||
| Distributions to non-controlling interest holders | (40.2 | ) | (35.0 | ) | (80.7 | ) | (76.9 | ) | ||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Other Data: | ||||||||||||||||
| Number of surgical facilities as of the end of period | 167 | 152 | 167 | 152 | ||||||||||||
| Number of consolidated surgical facilities as of the end of period | 127 | 119 | 127 | 119 | ||||||||||||
| Cases | 166,520 | 155,185 | 319,912 | 306,139 | ||||||||||||
| Revenue per case | $ | 4,577 | $ | 4,302 | $ | 4,625 | $ | 4,357 | ||||||||
| Adjusted EBITDA (1) | $ | 118.3 | $ | 100.2 | $ | 215.8 | $ | 190.3 | ||||||||
| Adjusted EBITDA margin (2) | 15.5 | % | 15.0 | % | 14.6 | % | 14.3 | % | ||||||||
| Adjusted net income per share attributable to common stockholders - Basic (1) | $ | 0.21 | $ | 0.29 | $ | 0.31 | $ | 0.37 | ||||||||
| Adjusted net income per share attributable to common stockholders - Diluted (1) | $ | 0.21 | $ | 0.28 | $ | 0.31 | $ | 0.37 | ||||||||
| Free Cash Flow (1) | $ | 31.6 | $ | 7.7 | $ | 22.4 | $ | 28.2 | ||||||||
(1) A reconciliation of these non-GAAP financial measures appears below.
(2) Defined as Adjusted EBITDA as a % of Revenues.
| SURGERY PARTNERS, INC. Supplemental Information (Dollars in millions, except per case amounts) (Unaudited) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Same-facility Information (1): | ||||||||||||||||
| Cases | 178,366 | 171,631 | 344,532 | 335,446 | ||||||||||||
| Case growth | 3.9 | % | N/A | 2.7 | % | N/A | ||||||||||
| Revenue per case | $ | 4,349 | $ | 4,114 | $ | 4,451 | $ | 4,155 | ||||||||
| Revenue per case growth | 5.7 | % | N/A | 7.1 | % | N/A | ||||||||||
| Number of work days in the period | 64 | 64 | 128 | 128 | ||||||||||||
| Case growth (days adjusted) | 3.9 | % | N/A | 2.7 | % | N/A | ||||||||||
| Revenue growth (days adjusted) | 9.9 | % | N/A | 10.0 | % | N/A | ||||||||||
(1) Same-facility information includes cases and revenues from our consolidated and non-consolidated surgical facilities (excluding facilities acquired in new markets or divested during the current and prior periods).
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Segment Revenues: | ||||||||||||||||
| Surgical Facility Services | $ | 730.4 | $ | 650.2 | $ | 1,423.1 | $ | 1,299.2 | ||||||||
| Ancillary Services | 31.7 | 17.4 | 56.4 | 34.6 | ||||||||||||
| Total revenues | $ | 762.1 | $ | 667.6 | $ | 1,479.5 | $ | 1,333.8 | ||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Adjusted EBITDA: | ||||||||||||||||
| Surgical Facility Services | $ | 143.0 | $ | 126.7 | $ | 269.7 | $ | 245.5 | ||||||||
| Ancillary Services | 0.1 | (0.1 | ) | (1.3 | ) | (1.5 | ) | |||||||||
| All other | (24.8 | ) | (26.4 | ) | (52.6 | ) | (53.7 | ) | ||||||||
| Total Adjusted EBITDA | $ | 118.3 | $ | 100.2 | $ | 215.8 | $ | 190.3 | ||||||||
| SURGERY PARTNERS, INC. Reconciliation of Non-GAAP Financial Measures (Dollars in millions, except per share amounts, shares in thousands) (Unaudited) | ||||||||||||||||
| The following table reconciles Adjusted EBITDA to income before income taxes in the reported consolidated financial information, the most directly comparable GAAP financial measure: | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Income before income taxes | $ | 33.3 | $ | 49.9 | $ | 62.0 | $ | 49.5 | ||||||||
| Net income attributable to non-controlling interests | (43.9 | ) | (38.8 | ) | (80.6 | ) | (64.9 | ) | ||||||||
| Interest expense, net | 51.5 | 47.7 | 98.8 | 94.5 | ||||||||||||
| Depreciation and amortization | 34.8 | 24.4 | 68.5 | 58.1 | ||||||||||||
| Equity-based compensation expense | 15.1 | 4.6 | 20.0 | 8.8 | ||||||||||||
| Transaction, integration and acquisition costs (1) | 20.8 | 13.0 | 39.7 | 25.8 | ||||||||||||
| Net loss (gain) on disposals, consolidations and deconsolidations | 5.3 | (8.8 | ) | 6.8 | 1.7 | |||||||||||
| Litigation settlements and regulatory change impact (2) | 1.1 | 1.7 | (0.1 | ) | 9.7 | |||||||||||
| Loss on debt extinguishment | 5.1 | — | 5.1 | — | ||||||||||||
| Undesignated derivative activity | — | — | — | 0.6 | ||||||||||||
| Other | (4.8 | ) | 6.5 | (4.4 | ) | 6.5 | ||||||||||
| Adjusted EBITDA (3) | $ | 118.3 | $ | 100.2 | $ | 215.8 | $ | 190.3 | ||||||||
(1) This amount includes transaction and integration costs of
This amount includes transaction and integration costs of
(2) This amount includes a litigation settlement loss of
This amount includes litigation settlements gain of
(3) We use Adjusted EBITDA as a measure of financial performance. Adjusted EBITDA is a key measure used by management to assess operating performance, make business decisions and allocate resources. Non-controlling interests represent the interests of third parties, such as physicians, and in some cases, healthcare systems that own an interest in surgical facilities that we consolidate for financial reporting purposes. We believe that it is helpful to investors to present Adjusted EBITDA as defined above because it excludes the portion of net income attributable to these third-party interests and clarifies for investors our portion of Adjusted EBITDA generated by our surgical facilities and other operations. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be considered in isolation or as a substitute for net income, operating income or any other measure calculated in accordance with GAAP. The items excluded from Adjusted EBITDA are significant components in understanding and evaluating our financial performance. We believe such adjustments are appropriate, as the magnitude and frequency of such items can vary significantly and are not related to the assessment of normal operating performance. Our calculation of Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies.
The following table provides supplemental information for Adjusted EBITDA related to unconsolidated affiliates:
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Adjusted EBITDA related to unconsolidated affiliates: | |||||||||||||||
| Management fee revenues (1)(2) | $ | 6.8 | $ | 5.2 | $ | 13.3 | $ | 10.1 | |||||||
| Equity in earnings of unconsolidated affiliates (2) | 4.4 | 2.6 | 7.1 | 5.9 | |||||||||||
| Plus: | |||||||||||||||
| Start-up costs related to unconsolidated de novo surgical facilities (3) | 0.6 | 0.4 | 0.9 | 0.8 | |||||||||||
| Adjusted EBITDA related to unconsolidated affiliates | $ | 11.8 | $ | 8.2 | $ | 21.3 | $ | 16.8 | |||||||
(1) Includes management and administrative service fees derived from the non-consolidated facilities that the Company accounts for under the equity method and management of surgical facilities in which it does not own an interest. Management fee revenues are included in Revenues on the Consolidated Statements of Operations.
(2) Included as a component of income before income taxes in the Adjusted EBITDA reconciliation table above.
(3) Start-up costs related to de novo surgical facilities are included in Transaction, integration and acquisition costs in the Adjusted EBITDA reconciliation table above.
The following table reconciles Free Cash Flow to net cash provided by operating activities in the reported condensed consolidated financial information, the most directly comparable GAAP financial measure:
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net cash provided by operating activities | $ | 82.8 | $ | 52.1 | $ | 123.5 | $ | 126.6 | |||||||
| Less: Maintenance capital expenditures | (11.0 | ) | (9.4 | ) | (20.4 | ) | (21.5 | ) | |||||||
| Less: Distributions to non-controlling interest holders | (40.2 | ) | (35.0 | ) | (80.7 | ) | (76.9 | ) | |||||||
| Free Cash Flow (1) | $ | 31.6 | $ | 7.7 | $ | 22.4 | $ | 28.2 | |||||||
| Growth capital expenditures | $ | (15.9 | ) | $ | (16.4 | ) | $ | (27.5 | ) | $ | (28.6 | ) | |||
| Maintenance capital expenditures | (11.0 | ) | (9.4 | ) | (20.4 | ) | (21.5 | ) | |||||||
| Purchases of property and equipment | $ | (26.9 | ) | $ | (25.8 | ) | $ | (47.9 | ) | $ | (50.1 | ) | |||
(1) Free Cash Flow is defined as cash flow provided by operating activities, less distributions to non-controlling interest holders and less maintenance capital expenditures, which are capital expenditures primarily to maintain our existing facilities. We use the non-GAAP measure of Free Cash Flow as a measure of liquidity to determine amounts we can reinvest in our core businesses, such as amounts available to make acquisitions and invest in growth projects. Our calculation of Free Cash Flow may not be comparable to similarly titled measures reported by other companies.
From time to time, the Company incurs certain non-recurring gains or losses that are normally non-operational in nature and management does not consider relevant in assessing its ongoing operating performance. When significant, Surgery Partners’ management and the Company's Board of Directors typically exclude these gains or losses when evaluating the Company’s operating performance and in certain instances when evaluating performance for incentive compensation purposes. Additionally, management believes that certain investors and equity analysts exclude these or similar items when evaluating the Company’s current or future operating performance and in making informed investment decisions regarding the Company. Accordingly, the Company provides adjusted net income attributable to common stockholders and adjusted net income per share attributable to common stockholders as supplements to the comparable GAAP financial measures. Adjusted net income attributable to common stockholders and adjusted net income per share attributable to common stockholders should not be considered measures of financial performance under GAAP, and the items excluded from such measures are significant components in understanding and assessing financial performance. These measures should not be considered in isolation or as an alternative to the comparable GAAP measures as presented in the consolidated financial statements.
The following table reconciles net income as reflected in the consolidated statements of operations to adjusted net income attributable to common stockholders used to calculate adjusted net income per share attributable to common stockholders:
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Consolidated Statements of Operations Data: | |||||||||||||||
| Net income | $ | 28.4 | $ | 57.7 | $ | 52.7 | $ | 58.9 | |||||||
| Plus (minus): | |||||||||||||||
| Net income attributable to non-controlling interests | (43.9 | ) | (38.8 | ) | (80.6 | ) | (64.9 | ) | |||||||
| Equity-based compensation expense | 15.1 | 4.6 | 20.0 | 8.8 | |||||||||||
| Transaction, integration and acquisition costs | 20.8 | 13.0 | 39.7 | 25.8 | |||||||||||
| Net loss (gain) on disposals, consolidations and deconsolidations | 5.3 | (8.8 | ) | 6.8 | 1.7 | ||||||||||
| Litigation settlements and regulatory change impact | 1.1 | 1.7 | (0.1 | ) | 9.7 | ||||||||||
| Loss on debt extinguishment | 5.1 | — | 5.1 | — | |||||||||||
| Other | (4.8 | ) | 6.5 | (4.4 | ) | 6.5 | |||||||||
| Adjusted net income attributable to common stockholders | $ | 27.1 | $ | 35.9 | $ | 39.2 | $ | 46.5 | |||||||
| Adjusted net income per share attributable to common stockholders | |||||||||||||||
| Basic | $ | 0.21 | $ | 0.29 | $ | 0.31 | $ | 0.37 | |||||||
| Diluted | $ | 0.21 | $ | 0.28 | $ | 0.31 | $ | 0.37 | |||||||
| Weighted average common shares outstanding | |||||||||||||||
| Basic | 126,134 | 125,718 | 126,053 | 125,463 | |||||||||||
| Diluted | 127,296 | 127,370 | 127,359 | 127,017 | |||||||||||
Contact
Surgery Partners Investor Relations
(615) 234-8940
IR@surgerypartners.com
FAQ
What were Surgery Partners' (SGRY) Q2 2024 revenue and growth figures?
How did Surgery Partners' (SGRY) Adjusted EBITDA perform in Q2 2024?
What is Surgery Partners' (SGRY) updated guidance for full-year 2024?
How much did Surgery Partners (SGRY) spend on acquisitions in Q2 2024?
